AlphAIalphai — Financial news for AI agents
rttnews.comAUG 261 min read$SMMT

Summit Therapeutics Stock Rises 8%

Summit Therapeutics (SMMT) shares rose 7.78% to $14.40 Wednesday, possibly due to partner Akeso's positive Phase III trial results for ivonescimab in advanced biliary tract cancer. The stock traded between $14.11 and $15.10, with volume at 7.52 million shares. Akeso reported statistically significant overall survival benefits in the HARMONi-GI1 study.

Original reporting
rttnews.com
Published Aug 26, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 7:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
8/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The interim Phase III results show statistically significant overall survival benefit, a key catalyst for Summit's valuation.

02

Market read

The trial news directly drove a near‑double‑digit price move, indicating high trader interest.

03

What to watch

Regulatory review timelines and potential competition from other checkpoint inhibitors.

Relevance 8/10Novelty 8/10Timing: today

Background

Summit Therapeutics (NASDAQ:SMMT) partners with Akeso Biopharma; the drug ivonescimab targets PD‑L1 in biliary tract cancer.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Summit Therapeutics shares jumped 7.8% after partner Akeso reported positive Phase III interim results for ivonescimab in advanced biliary tract cancer.

Expected impact

Expect continued short‑term rally; potential 5‑10% upside over the next few days.

Evidence & confidence

Phase III interim superiority in overall survival is material for a biotech; the market reacted immediately with a sizable price jump.

Market effects

Sector

Positive data may lift other companies developing biliary or GI oncology therapies.

Regional

US biotech sector gains momentum from the news.

Global

Highlights continued strength of late‑stage oncology pipelines worldwide.

Counterpoint

What could challenge this read

If the final data fail to confirm interim results, the rally could reverse sharply.

Key entities

  • Company
    Summit Therapeutics Inc.

    Biotech developing oncology therapies.

  • Company
    Akeso Biopharma

    Partner conducting the trial.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 27
$SMMTHighAI 8/10

Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

Summit Therapeutics (SMMT) rose 8.5% after partner Akeso's Phase III trial showed ivonescimab plus chemotherapy improved survival rates in advanced biliary tract cancer. The drug's success adds to its lung cancer data and ongoing FDA review. Summit projects $897.3M revenue and $169.7M earnings by 2029, with analysts estimating potential $2.5B revenue by 2029.

simplywall.st2 min
AUG 27
$SMMTHighAI 9/10

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics (SMMT) shares rose 6.5% after partner Akeso reported positive phase III study results for ivonescimab in biliary tract cancer, showing superiority over AstraZeneca's (AZN) Imfinzi. The study met primary and secondary endpoints, including overall survival. Summit holds exclusive licensing rights for ivonescimab in multiple regions, excluding China. Year-to-date, SMMT shares are down 18.6% against industry growth of 3.2%.

finance.yahoo.com2 min
AUG 26
$SMMTHighAI 9/10

Summit Therapeutics Shares Surge on Positive Phase III Data From Chinese Partner Akeso

Summit Therapeutics (SMMT) shares rose 8% to $14.40 after partner Akeso reported positive Phase III trial results for ivonescimab in advanced biliary tract cancer, meeting primary and secondary endpoints. The drug, a bispecific antibody, is key to Summit's pipeline, with an FDA decision pending for NSCLC. Investors consider potential and risks, including cash burn and recent stock offering.

asktraders.com2 min
AUG 26
$SMMTHighAI 9/10

Why is Summit Therapeutics stock surging today?

Summit Therapeutics (SMMT) stock rose 8.5% in pre-market trading after positive clinical trial data for its drug ivonescimab. Partner Akeso reported success in a Phase III study for advanced biliary tract cancer, and Summit published results showing reduced disease progression risk in lung cancer. Analysts Guggenheim and Bernstein SocGen updated their ratings and price targets. The rally was company-specific, with the broader market showing little movement.

investing.com2 min
AUG 26
$SMMTHighAI 9/10

Summit Therapeutics stock jumps on partner’s cancer trial data

Summit Therapeutics (SMMT) shares rose 7.75% after its partner Akeso's Phase III cancer study met primary and key secondary endpoints. The study showed ivonescimab plus chemotherapy improved overall survival in advanced biliary tract cancer. Analysts had mixed reactions, with H.C. Wainwright maintaining a Neutral rating and Guggenheim reiterating a Buy with a $38 price target.

investing.com2 min